Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 1081 | Mycophenolate Sodium 180mg Tablet | L04AA06520T1001XX | A* | Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids | 720 mg twice daily | |
| 1082 | Mycophenolate Sodium 360mg Tablet | L04AA06520T1002XX | A* | Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids | 720 mg twice daily | |
| 1083 | Nalbuphine HCl 10 mg/ml Injection | N02AF02110P3001XX | B | i) Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate ii) As a supplement to balanced anesthesia, for preoperative and postoperative analgesia and for obstetrical analgesia during labor and delivery | i) ADULT: 10mg SC, IM or IV repeated every 3-6 hours as necessary. Max. single dose: 20mg Max. total daily dose: 160mg ii) Induction: 0.3 – 3 mg/kg IV to be administered over 10 to 15 min Maintenance: 0.25 – 0.50 mg / kg in single IV administration as required. | |
| 1084 | Naloxone HCl 0.02mg/ml Injection | V03AB15-110-P30-01-XX | B | For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage | None | 0.005 - 0.01 mg/kg body weight repeated at intervals of 2 - 3 minutes according to the patient's needs by IM, IV or SC |
| 1085 | Naloxone HCl 0.4mg/ml Injection | V03AB15-110-P30-02-XX | B | For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage | None | Initially 0.4 - 2 mg IV repeated at intervals of 2 - 3 minutes according to patient's needs |
| 1086 | Naltrexone HCl 50 mg Tablet | N07BB04110T1001XX | A | Adjunct in relapse prevention treatment in detoxified formerly opioid-dependant patients | Initial 25 mg may be increased to 50 mg. Maintenance: 350 mg weekly; administered as 50 mg daily. Dosing interval may be lengthened to improve compliance; 100 mg on alternate days or 150 mg every third day | |
| 1087 | Naproxen 250mg Tablet | M01AE02-000-T10-01-XXX | A/KK | i) Rheumatic arthritis, osteoarthritis and ankylosing spondylitis ii) Acute gout iii) Muscular skeletal disorder, dysmenorrhoea | None | i) 0.5 - 1 g daily in 2 divided doses ii) 750 mg initially then 250 mg 8 hourly iii) 500 mg initially then 250 mg every 6 - 8 hour as required Max: 1g daily |
| 1088 | Naproxen Sodium 275mg Tablet | M01AE02-520-T10-01-XXX | A | i) Rheumatic arthritis, osteoarthritis and alkylosing spondylitis ii) Acute gout iii) Muscular skeletal disorder and dysmenorrhoea | None | i: 275mg bd ii: Initial: 825mg followed by 275mg every 8 hrs as necesssary iii. Initial: 550mg followed by 275 every 6-8 hrs as necessary. |
| 1089 | Neomycin 0.5% Cream | D06AX04256G1001XX | B | Infections of the skin due to susceptible organisms | Apply sparingly to affected area up to 3 times daily (For short term use, 1 - 2 weeks) | |
| 1090 | Neomycin 0.5% in Betamethasone 17-Valerate 0.01% Cream | D07CC01-947-G10-01-XXX | B | Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo | None | Apply sparingly to affected area 2 - 3 times daily. (May cause sensitisation to neomycin. Use with caution) |
| 1091 | Neomycin 0.5% in Betamethasone 17-Valerate 0.01% Ointment | D07CC01-947-G50-01-XXX | B | Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo | None | Apply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to Neomycin. Use with caution) |
| 1092 | Neomycin 0.5% in Betamethasone 17-Valerate 0.1% Cream | D07CC01-947-G10-02-XXX | A | Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo | None | Apply sparingly to affected area 2 - 3 times daily (May cause sensitisation to neomycin. Use with caution) |
| 1093 | Neomycin 0.5% in Betamethasone 17-Valerate 0.1% Ointment | D07CC01-947-G50-02-XXX | A | Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo | Apply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to neomycin. Use with caution) | |
| 1094 | Neomycin 0.5% Ointment | D06AX04256G5001XX | B | Infections of the skin due to susceptible organisms | Apply sparingly to affected area up to 3 times daily (For short term use, 1- 2 weeks) | |
| 1095 | Neostigmine Methylsulphate 2.5mg/ml Injection | N07AA01-183-P30-02-XXX | B | i) Symptomatic treatment of myasthenia gravis where oral therapy is impractical ii) Reversal of the effects of non-depolarizing neuromuscular blockade iii)The management of post-operative distension, paralytic ileus and urinary retention, where mechanical obstruction has been out-ruled | i) ADULT: 1 - 2.5 mg at suitable intervals by SC, IM or IV. Usual total daily dose 5 - 20 mg. CHILD: 0.1mg IM. Titrated in the range of 0.05mg - 0.25mg. NEONATE: 50 - 250 mcg every 4 hours ii) By IV injection over 1 minute, 50 - 70 mcg/kg (maximum 5 mg and 2.5mg for children) after or with atropine sulphate 0.6 - 1.2 mg iii) Adults: SC or IM 0.5 - 2.5mg. Children: SC or IM 0.125mg - 1mg | |
| 1096 | Nepafenac 0.1% ophthalmic solution | S01BC10-000-D20-01-XXX | A* | Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. | None | One drop 3 times/day beginning 1 day prior to cataract surgery, continued on the day of surgery and up to 60 days of the postoperative period as directed by the clinician. An additional drop should be administered 30 to 120 minutes prior to surgery. |
| 1097 | Netilmicin Sulphate 100 mg/2 ml Injection | J01GB07183P3002XX | A | Systemic infections | ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day | |
| 1098 | Netilmicin Sulphate 150 mg/2 ml Injection | J01GB07183P3003XX | A | Systemic infections | ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day | |
| 1099 | Netilmicin Sulphate 50 mg/2 ml Injection | J01GB07183P3001XX | A | Systemic infections | ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day | |
| 1100 | Neuro Polyvalent Snake Antivenom Injection | Nil | B | Passive immunisation against poisonous of a range of haematotoxic snakebites neurotoxic snakebites, based on the type of snake identified. | For initial dose, at least 20mL of reconstituted serum should be given by slow intravenous infusion (not more than 1mL/minute). If symptoms still persist, the second dose should be repeated 2 hours or even earlier after the initial dose. The further dose should be repeated every 6 hours according to the clinical symptoms. Administration: Draw 10mL of the sterile water for injection to the freeze-dried antivenin, shake well to dissolve the contents until the serum became clear colourless or pale yellow liquid, ready for administration. | |
| 1101 | Nevirapine 200mg Tablet | J05AG01-000-T10-01-XXX | A/KK | Treatment of HIV-1 infection in combination with other antiretroviral agents | None | Combined with other antiretrovirals: 200 mg once daily for the 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-introduce at a lower dose for the 1st 14 days if treatment is interrupted for >7 days,necessitate reintroduction at a lower dose for the first 14 days. |
| 1102 | Nevirapine 50mg/5ml Oral Suspension | J05AG01-000-L80-01-XXX | A/KK | Treatment of HIV-1 infection in combination with other antiretroviral agents | None | The total daily dose should not exceed 400mg. Nevirapine may be dosed in paediatric patients either by body surface area (BSA) or by body weight. i)By BSA using the Mosteller formula: the recommended oral dose for paediatric patients of all ages is 150 mg/m2 once daily for 2 weeks followed by 150 mg/m2 twice daily thereafter. ii)By body weight: <8 years of age: 4 mg/kg once daily for 2 weeks followed by 7 mg/kg twice daily thereafter. ≥8 years: 4 mg/kg once daily for 2 weeks followed by 4 mg/kg twice daily thereafter. |
| 1103 | Nicardipine Hydrochloride 1mg/ml Solution for Infusion | C08CA04-110-P31-01-xxx | A | Treatment of hypertensive crisis | None | i) Adult Dose Initial dose Treatment should start with the continuous administration of nicardipine at a rate of 3-5 mg/h for 15 minutes. Rates can be increased by increments of 0.5 or 1 mg every 15 minutes. The infusion rate should not exceed 15 mg/h. Maintenance dose When the target pressure is reached, the dose should be reduced progressively, usually to between 2 and 4 mg/h, to maintain the therapeutic efficacy. ii) Paediatric Dose Nicardipine should only be used for life-threatening hypertension in paediatric intensive care settings or postoperative contexts. Initial dose: In case of emergency, a starting dose of 0.5 to 5 mcg/kg/min is recommended. Maintenance dose: The maintenance dosage of 1 to 4mcg/kg/min is recommended |
| 1104 | Nicotine 1 mg/spray Mouth Spray | N07BA01-000-A42-01-xxx | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | None | 1 mg of nicotine per metered spray dose, up to 3 sprays per hour for administration into the oral cavity |
| 1105 | Nicotine 10mg/16hr Transdermal Patch | N07BA01000M7005XX | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | The patch should be apply to an intact area of the skin upon waking up in the morning and removed at bedtime. Heavy smoker (those smoking 15 or more cigarettes in a 24-hour period): Step 1: 25mg/16 hours patch and use one patch daily for 8 weeks. Step 2: One 15mg/16hours patch should be daily for 2 weeks Step 3: One 10mg/16 hours patch daily for 2 weeks. Light smokers (those smoking less than 15 cigarettes in a 24-hour period): Step 1: 15mg/16hours patch for 8 weeks Step 2: 10mg/16hours for the final 4 weeks. Combination therapy with the patch (Flexible smoking cessation format) for fast relief of cravings in: i) Highly dependent smokers; or ii) Smokers who experience breakthrough cravings; or iii) Those who have failed single NRT treatment | |
| 1106 | Nicotine 14mg/24hr Transdermal Patch | N07BA01000M7002XX | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | The patch should be apply to an intact area of the skin upon waking up in the morning and removed at 24hrs. Smokers of >10 cigarettes/day: 21 mg/day for 6 wk, then 14 mg/day for 2 wk; finish w/ 7 mg/day for 2 wk. Smokers of ≤10 cigarettes/day: 14 mg/day for 6 wk, then 7 mg/day for 2 wk. | |
| 1107 | Nicotine 15mg/16hr Transdermal Patch | N07BA01000M7006XX | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | The patch should be apply to an intact area of the skin upon waking up in the morning and removed at bedtime. Heavy smoker (those smoking 15 or more cigarettes in a 24-hour period): Step 1: 25mg/16 hours patch and use one patch daily for 8 weeks. Step 2: One 15mg/16hours patch should be daily for 2 weeks Step 3: One 10mg/16 hours patch daily for 2 weeks. Light smokers (those smoking less than 15 cigarettes in a 24-hour period): Step 1: 15mg/16hours patch for 8 weeks Step 2: 10mg/16hours for the final 4 weeks. Combination therapy with the patch (Flexible smoking cessation format) for fast relief of cravings in: i) Highly dependent smokers; or ii) Smokers who experience breakthrough cravings; or iii) Those who have failed single NRT treatment. | |
| 1108 | Nicotine 21mg/24hr Transdermal Patch | N07BA01000M7003XX | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | The patch should be apply to an intact area of the skin upon waking up in the morning and removed at 24hrs. Smokers of >10 cigarettes/day: 21 mg/day for 6 wk, then 14 mg/day for 2 wk; finish w/ 7 mg/day for 2 wk. Smokers of ≤10 cigarettes/day: 14 mg/day for 6 wk, then 7 mg/day for 2 wk. | |
| 1109 | Nicotine 25mg/16hr Transdermal Patch | N07BA01-000-M70-07-001 | A/KK | For the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms thereby facilitating smoking cessation in smokers motivated to quit. Advice and support normally improve the success rate. | The patch should be apply to an intact area of the skin upon waking up in the morning and removed at bedtime. Heavy smoker (those smoking 15 or more cigarettes in a 24-hour period): Step 1: 25mg/16 hours patch and use one patch daily for 8 weeks. Step 2: One 15mg/16hours patch should be daily for 2 weeks Step 3: One 10mg/16 hours patch daily for 2 weeks. Light smokers (those smoking less than 15 cigarettes in a 24-hour period): Step 1: 15mg/16hours patch for 8 weeks Step 2: 10mg/16hours for the final 4 weeks. Combination therapy with the patch (Flexible smoking cessation format) for fast relief of cravings in: i) Highly dependent smokers; or ii) Smokers who experience breakthrough cravings; or iii) Those who have failed single NRT treatment. | |
| 1110 | Nicotine 2mg Gum | N07BA01000M9901XX | A/KK | For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. | Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.) |